Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor

International Journal of Oncology

Volumn 49, Issue 3, 2016, Pages 1164-1174

  Caporali, Simona ^a   Alvino, Ester ^b   Lacal, Pedro Miguel ^a   Levati, Lauretta ^a   Giurato, Giorgio ^c,d   Memoli, Domenico ^c   Caprini, Elisabetta ^a   Cappellini, Gian Carlo Antonini ^a   D'Atri, Stefania ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^c Laboratory of Molecular Medicine and Genomics   (Italy)

^d UNIVERSITY OF SALERNO   (Italy)

Author keywords

Bevacizumab; BRAF; Dabrafenib; Drug resistance; GSK2126458A; Invasion; Melanoma

Indexed keywords

BEVACIZUMAB; DABRAFENIB; GELATINASE B; MAMMALIAN TARGET OF RAPAMYCIN; OMIPALISIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; B RAF KINASE; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, HUMAN; OXIME; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

A375 CELL LINE; ARTICLE; CANCER INHIBITION; CELL INVASION; CONTROLLED STUDY; DRUG RESISTANCE; DRUG TARGETING; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; MELANOMA; METABOLISM; MUTATION; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; MELANOMA; MUTATION; NEOPLASM INVASIVENESS; OXIMES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84978499672     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3594     Document Type: Article

References (58)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
2. Lopez-Bergami P: The role of mitogen-and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res 24: 902-921, 2011.
3. Sullivan RJ and Flaherty K: MAP kinase signaling and inhibition in melanoma. Oncogene 32: 2373-2379, 2013.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al; BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516, 2011.
5. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et al; METRIC Study Group: Improved survival with MEK inhibition in BRAFmutated melanoma. N Engl J Med 367: 107-114, 2012.
6. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365, 2012.
7. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367: 1694-1703, 2012.
8. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, et al: Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372: 30-39, 2015.
9. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386: 444-451, 2015.
10. Sullivan RJ and Flaherty KT: Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 49: 1297-1304, 2013.
11. Holderfield M, Deuker MM, McCormick F and McMahon M: Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 14: 455-467, 2014.
12. Fedorenko IV, Gibney GT, Sondak VK and Smalley KSM: Beyond BRAF: Where next for melanoma therapy? Br J Cancer 112: 217-226, 2015.
13. Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, Ottaviano V and Queirolo P: BRAF-mutant melanoma: Treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther 8: 157-168, 2015.
14. Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, Buchanan S, Henry JR, Starling JJ and Peng SB: Reactivation of mitogenactivated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem 287: 28087-28098, 2012.
15. Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, et al: PDGFR up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 5: 1926-1941, 2014.
16. Wang J, Huang SK, Marzese DM, Hsu SC, Kawas NP, Chong KK, Long GV, Menzies AM, Scolyer RA, Izraely S, et al: Epigenetic changes of EGFR have an important role in BRAF inhibitorresistant cutaneous melanomas. J Invest Dermatol 135: 532-541, 2015.
17. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y and Sznol M: PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23: 190-200, 2010.
18. Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, et al: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 3: 158-167, 2013.
19. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105: 3041-3046, 2008.
20. Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li L, Gimotty PA, Wilson M, Hayden J, et al: MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene 33: 1850-1861, 2014.
21. Zubrilov I, Sagi-Assif O, Izraely S, Meshel T, Ben-Menahem S, Ginat R, Pasmanik-Chor M, Nahmias C, Couraud PO, Hoon DSB, et al: Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. Cancer Lett 361: 86-96, 2015.
22. Sanchez-Laorden B, Viros A, Girotti MR, Pedersen M, Saturno G, Zambon A, Niculescu-Duvaz D, Turajlic S, Hayes A, Gore M, et al: BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal 7: ra30, 2014.
23. Vergani E, Vallacchi V, Frigerio S, Deho P, Mondellini P, Perego P, Cassinelli G, Lanzi C, Testi MA, Rivoltini L, et al: Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. Neoplasia 13: 1132-1142, 2011.
24. Li H and Durbin R: Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754-1760, 2009.
25. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al: The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297-1303, 2010.
26. Yang H and Wang K: Genomic variant annotation and prioritization with ANN OVAR and wANN OVAR. Nat Protoc 10: 1556-1566, 2015.
27. Pepponi R, Marra G, Fuggetta MP, Falcinelli S, Pagani E, Bonmassar E, Jiricny J and D'Atri S: The effect of O6-alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin. J Pharmacol Exp Ther 304: 661-668, 2003.
28. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J and D'Atri S: DNA damage induced by temozolomide signals to both ATM and ATR: Role of the mismatch repair system. Mol Pharmacol 66: 478-491, 2004.
29. Ruffini F, D'Atri S and Lacal PM: Neuropilin-1 expression promotes invasiveness of melanoma cells through vascular endothelial growth factor receptor-2-dependent and-independent mechanisms. Int J Oncol 43: 297-306, 2013.
30. Naber HP, Wiercinska E, Ten Dijke P and van Laar T: Spheroid assay to measure TGF-induced invasion. J Vis Exp 57: e3337, 2011.
31. Merz C, Strecker A, Sykora J, Hill O, Fricke H, Angel P, Gieffers C and Peterziel H: Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro. Anticancer Drugs 26: 716-727, 2015.
32. Lacal PM, Failla CM, Pagani E, Odorisio T, Schietroma C, Falcinelli S, Zambruno G and D'Atri S: Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol 115: 1000-1007, 2000.
33. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, et al: Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res 20: 4449-4458, 2014.
34. Smalley KS, Lioni M and Herlyn M: Life isn't flat: Taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim 42: 242-247, 2006.
35. Lacal PM, Ruffini F, Pagani E and D'Atri S: An autocrine loop directed by the vascular endothelial growth factor promotes invasiveness of human melanoma cells. Int J Oncol 27: 1625-1632, 2005.
36. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, et al: BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 19: 393-403, 2013.
37. Beazley-Long N, Gaston K, Harper SJ, Orlando A and Bates DO: Novel mechanisms of resistance to vemurafenib in melanoma-V600E B-Raf reversion and switching VEGF-A splice isoform expression. Am J Cancer Res 5: 433-441, 2014.
38. Ferrara N, Hillan KJ, Gerber HP and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400, 2004.
39. Keating GM: Bevacizumab: A review of its use in advanced cancer. Drugs 74: 1891-1925, 2014.
40. Koch S, Tugues S, Li X, Gualandi L and Claesson-Welsh L: Signal transduction by vascular endothelial growth factor receptors. Biochem J 437: 169-183, 2011.
41. Goel HL and Mercurio AM: VEGF targets the tumour cell. Nat Rev Cancer 13: 871-882, 2013.
42. Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, Gonzalez FJ and Fabra A: Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 123: 1151-1161, 2004.
43. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L and Gilmer TM: Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11: 909-920, 2012.
44. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 141: 52-67, 2010.
45. Gialeli C, Theocharis AD and Karamanos NK: Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278: 16-27, 2011.
46. Orgaz JL and Sanz-Moreno V: Emerging molecular targets in melanoma invasion and metastasis. Pigment Cell Melanoma Res 26: 39-57, 2013.
47. Ghosh S, Basu M and Roy SS: ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. J Biol Chem 287: 15001-15015, 2012.
48. Claesson-Welsh L and Welsh M: VEGFA and tumour angiogenesis. J Intern Med 273: 114-127, 2013.
49. Carlino MS, Gowrishankar K, Saunders CAB, Pupo GM, Snoyman S, Zhang XD, Saw R, Becker TM, Kefford RF, Long GV, et al: Antiproliferative effects of continued mitogenactivated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther 12: 1332-1342, 2013.
50. Chan MMK, Haydu LE, Menzies AM, Azer MWF, Klein O, Lyle M, Clements A, Guminski A, Kefford RF and Long GV: The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition. Cancer 120: 3142-3153, 2014.
51. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer N K, Levesque MP, Dummer R, McMahon M and Stuart DD: Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494: 251-255, 2013.
52. Hartsough EJ, Basile KJ and Aplin AE: Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol Cancer Res 12: 795-802, 2014.
53. Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL and Kluger HM: Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 41: 375-384, 2010.
54. Jiang CC, Lai F, Thorne RF, Yang F, Liu H, Hersey P and Zhang XD: MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res 17: 721-730, 2011.
55. Shi H, Kong X, Ribas A and Lo RS: Combinatorial treatments that overcome PDGFRdriven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71: 5067-5074, 2011.
56. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, et al: Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 6: e28973, 2011.
57. Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, et al: Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 72: 969-978, 2012.
58. Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B and Ribas A: Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer 13: 83, 2014.